

This notice in TED website: <http://ted.europa.eu/udl?uri=TED:NOTICE:384724-2017:TEXT:EN:HTML>

**United Kingdom-Runcorn: Pharmaceutical products  
2017/S 188-384724**

**Contract notice**

**Supplies**

Directive 2014/24/EU

**Section I: Contracting authority**

I.1) **Name and addresses**

The NHS Commissioning Board (Operating Under the Name of NHS England)  
2nd Floor, Rutland House  
Runcorn  
WA7 2ES  
United Kingdom  
Telephone: +44 1928755227  
E-mail: [gemma.tomlinson1@nhs.net](mailto:gemma.tomlinson1@nhs.net)  
NUTS code: UK

**Internet address(es):**

Main address: <https://nhsengland.bravosolution.co.uk>

I.2) **Joint procurement**

The contract is awarded by a central purchasing body

I.3) **Communication**

The procurement documents are available for unrestricted and full direct access, free of charge, at: <https://nhsengland.bravosolution.co.uk>

Additional information can be obtained from the abovementioned address

Tenders or requests to participate must be submitted electronically via: <https://nhsengland.bravosolution.co.uk>

Tenders or requests to participate must be submitted to the abovementioned address

Electronic communication requires the use of tools and devices that are not generally available.

Unrestricted and full direct access to these tools and devices is possible, free of charge, at: <https://nhsengland.bravosolution.co.uk>

I.4) **Type of the contracting authority**

Ministry or any other national or federal authority, including their regional or local subdivisions

I.5) **Main activity**

Health

**Section II: Object**

II.1) **Scope of the procurement**

II.1.1) **Title:**

NHS National Generic Pharmaceuticals — Wave 11.

Reference number: CM/PHG/17/5530

II.1.2) **Main CPV code**

33600000

- II.1.3) **Type of contract**  
Supplies
- II.1.4) **Short description:**  
Invitation to offer for NHS National Generic Pharmaceuticals — Wave 11.  
Offer reference number: CM/PHG/17/5530.  
Period of framework agreement: Dates detailed below with options to extend up to a maximum period of 26 months.  
Potential periods of call-offs under the framework agreement: Hospital Only Products — Central and South West (CESW) 1.7.2018 to 31.7.2019 (13 months); North West and Eastern and North London (NWLN) 1.7.2018 to 31.7.2019 (13 months) and South East and South London and North East and Yorkshire (LSNE) 1.7.2018 to 31.7.2019 (13 months).  
Oral Products — All Regions 1.7.2018 to 28.2.2019 (8 months).
- II.1.5) **Estimated total value**  
Value excluding VAT: 316 000 000.00 GBP
- II.1.6) **Information about lots**  
This contract is divided into lots: yes  
Tenders may be submitted for all lots
- II.2) **Description**
- II.2.1) **Title:**  
Wave 11 — Oral Products: All regions  
Lot No: CM/PHG/17/5530/01
- II.2.2) **Additional CPV code(s)**  
33600000  
33690000
- II.2.3) **Place of performance**  
NUTS code: UK  
Main site or place of performance:  
Please refer to Document 3, Schedule 8 in the ITO Documents for the list of purchasing points.
- II.2.4) **Description of the procurement:**  
NHS National Generic Pharmaceuticals — Wave 11.  
Offer reference number: CM/PHG/17/5530.  
Period of Framework Agreement: Dates detailed below with options to extend up to a maximum period of 26 months. Potential periods of call-offs under the framework agreement: Oral Products: All Regions 1.7.2018 to 28.2.2019 (8 months).
- II.2.5) **Award criteria**  
Price is not the only award criterion and all criteria are stated only in the procurement documents
- II.2.6) **Estimated value**  
Value excluding VAT: 16 000 000.00 GBP
- II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**  
Start: 01/07/2018  
End: 28/02/2019  
This contract is subject to renewal: no
- II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: yes

Description of options:

This framework agreement has the option to extend for a period of up to 8 months.

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Wave 11 — Hospital Only Products: CESW

Lot No: CM/PHG/17/5530/02

II.2.2) **Additional CPV code(s)**

33600000

33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 03, Schedule 8 in the ITO documents for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Generic Pharmaceuticals — Wave 11.

Offer Reference Number: CM/PHG/17/5530.

Period of framework agreement: dates detailed below with options to extend to a maximum period of 26 months.

Potential period of call-off under the framework agreement: Hospital Only Products: CESW 1.7.2018 to 31.7.2019 (13 months).

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

Value excluding VAT: 100 000 000.00 GBP

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/07/2018

End: 31/07/2019

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: yes

Description of options:

This framework agreement has the option to extend up to a period of 13 months.

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Wave 11 — Hospital Only Products — NWLN  
Lot No: CM/PHG/17/5530/02

II.2.2) **Additional CPV code(s)**

33600000  
33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Generic Pharmaceuticals — Wave 11.

Offer Reference Number: CM/PHG/17/5530.

Period of framework agreement: dates detailed below with options to extend to a maximum period of 26 months.

Potential period of call-off under the framework agreement: Hospital Only Products: NWLN 1.7.2018 to 31.7.2019 (13 months).

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

Value excluding VAT: 100 000 000.00 GBP

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/07/2018

End: 31/07/2019

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: yes

Description of options:

This framework agreement has the option to extend for up to a period of 13 months.

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

II.2) **Description**

II.2.1) **Title:**

Wave 11 — Hospital Only Products — LSNE  
Lot No: CM/PHG/17/5530/02

II.2.2) **Additional CPV code(s)**

33600000  
33690000

II.2.3) **Place of performance**

NUTS code: UK

Main site or place of performance:

Please refer to Document 3, Schedule 8 in the ITO documents for the list of purchasing points.

II.2.4) **Description of the procurement:**

NHS National Generic Pharmaceuticals — Wave 11.

Offer Reference Number: CM/PHG/17/5530.

Period of framework agreement: dates detailed below with options to extend to a maximum period of 26 months.

Potential period of call-off under the framework agreement: Hospital Only Products: LSNE 1.7.2018 to 31.7.2019 (13 months).

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

Value excluding VAT: 100 000 000.00 GBP

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Start: 01/07/2018

End: 31/07/2019

This contract is subject to renewal: no

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: yes

Description of options:

This framework agreement has the option to extend for a period of up to 13 months.

II.2.12) **Information about electronic catalogues**

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

**Section III: Legal, economic, financial and technical information**

III.1) **Conditions for participation**

III.1.1) **Suitability to pursue the professional activity, including requirements relating to enrolment on professional or trade registers**

III.1.2) **Economic and financial standing**

List and brief description of selection criteria:

Please refer to the award criteria contained within the ITO.

III.1.3) **Technical and professional ability**

III.1.5) **Information about reserved contracts**

III.2) **Conditions related to the contract**

III.2.2) **Contract performance conditions:**

III.2.3) **Information about staff responsible for the performance of the contract**

#### **Section IV: Procedure**

##### **IV.1) Description**

###### **IV.1.1) Type of procedure**

Open procedure

###### **IV.1.3) Information about a framework agreement or a dynamic purchasing system**

The procurement involves the establishment of a framework agreement

Framework agreement with several operators

###### **IV.1.4) Information about reduction of the number of solutions or tenders during negotiation or dialogue**

###### **IV.1.6) Information about electronic auction**

###### **IV.1.8) Information about the Government Procurement Agreement (GPA)**

The procurement is covered by the Government Procurement Agreement: yes

##### **IV.2) Administrative information**

###### **IV.2.1) Previous publication concerning this procedure**

###### **IV.2.2) Time limit for receipt of tenders or requests to participate**

Date: 06/11/2017

Local time: 13:00

###### **IV.2.3) Estimated date of dispatch of invitations to tender or to participate to selected candidates**

###### **IV.2.4) Languages in which tenders or requests to participate may be submitted:**

English

###### **IV.2.6) Minimum time frame during which the tenderer must maintain the tender**

Tender must be valid until: 06/03/2018

###### **IV.2.7) Conditions for opening of tenders**

Date: 06/11/2017

Local time: 13:00

Place:

Runcorn.

Information about authorised persons and opening procedure:

Commercial Medicines Unit Employee.

#### **Section VI: Complementary information**

##### **VI.1) Information about recurrence**

This is a recurrent procurement: no

##### **VI.2) Information about electronic workflows**

Electronic ordering will be used

Electronic invoicing will be accepted

Electronic payment will be used

##### **VI.3) Additional information:**

Responding to this notice:

Any supplier may be disqualified who does not respond to the following in the requisite manner:

1) Submission of expression of interest and procurement specific information

This procurement exercise will be conducted on the eTendering portal at [www.nhs.uk.bravosolution.co.uk](http://www.nhs.uk.bravosolution.co.uk)

Candidates wishing to be considered for this procurement exercise must register, and provide additional procurement specific information (if requested), through the eTendering portal as follows:

1.1) If not already registered, Candidates should register on the eTendering portal at [www.nhs.uk.bravosolution.co.uk](http://www.nhs.uk.bravosolution.co.uk) and click the link to register:

- accept the terms and conditions and click continue,
- enter your correct business and user details,
- note the username you chose and click 'Save' when complete,
- you will shortly receive an email with your unique password (please keep this secure).

1.2) Once registered, candidates must express interest as follows:

- a. login to the eTendering portal;
- b. select 'Response to ITT';
- c. select 'ITTs Open To All Suppliers';
- d. access listing related to this procurement, NHS National Generic Pharmaceuticals — Wave 11, and view details;
- e. click on 'Express interest' button at the top of the page.
- f. Once you have expressed interest, the ITT will move to 'My ITTs', where you can download additional documentation (if required), and construct your reply as instructed. You must then publish your reply using the 'Publish' button.

1.3) For any support in registering on the portal or submitting your expression of interest please contact the eTendering Help-desk at +44 800 368 4850 or [help@bravosolution.co.uk](mailto:help@bravosolution.co.uk)

2) General supplier information.

To manage and assess supplier information the Contracting Authority requests candidates provide their company profile in the Governments supplier information database, sid4gov, as follows:

2.1) If not already registered, Candidates must go to the following web page <https://sid4gov.cabinetoffice.gov.uk/> and select 'Register for sid4gov' at the bottom of the page. Key in details as requested to search for your company. If you do not have a D-U-N-S® Number, click on the link at the right of the page to obtain a number from D&B. Candidates must obtain a Dun & Bradstreet (D&B) D-U-N-S® Number to enable registration on sid4gov.

2.2) Once registration is complete you are able to create and update your sid4gov company profile. Candidates should ensure all the mandatory fields of their sid4gov profile are completed and up to date for each procurement exercise. D&B data will be supplied automatically by D&B.

2.3) For further help or information concerning sid4gov, please contact the sid4gov Helpdesk at: [support@nqc.com](mailto:support@nqc.com) or telephone +44 (0) 845 299 2994.

Other contracting authorities

The framework agreement is for the benefit of other participating NHS bodies (whether acting individually, or on behalf of, or together as members of any consortia) along with any other non-NHS bodies which the participants deem necessary for the delivery of services or goods to NHS bodies, local authorities, other government departments or non-departmental public bodies charged with the delivery of healthcare or health related services.

#### VI.4) **Procedures for review**

##### VI.4.1) **Review body**

The NHS Commissioning Board (Operating under the name of NHS England)  
Runcorn  
United Kingdom

##### VI.4.2) **Body responsible for mediation procedures**

##### VI.4.3) **Review procedure**

VI.4.4) **Service from which information about the review procedure may be obtained**

VI.5) **Date of dispatch of this notice:**

27/09/2017